IRTC iRhythm Holdings, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1388658 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.6%
TTM net income YoY25.0%
TTM EPS YoY27.3%
Revenue 3-yr CAGR21.8%
Net income 3-yr CAGR—
Margins
Gross margin72.3%
Operating margin-5.7%
Net margin-4.5%
FCF margin0.9%
EBITDA margin-3.3%
Returns
ROE-25.8%
ROA-3.7%
ROIC (approx.)—
Asset turnover0.82x
Leverage & solvency
Liabilities / assets83.8%
Debt / equity0.00x
Current ratio3.57x
Interest coverage-3.71x
Cash quality & payout
Operating cash flow / net income-1.44x
Accruals ratio-9.0%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $747.14M | $591.84M | $492.68M | $410.92M | $322.82M |
| Cost of revenue | $219.89M | $184.31M | $160.88M | $129.29M | $109.26M |
| Gross profit | $527.25M | $407.53M | $331.81M | $281.63M | $213.57M |
| R&D expense | $84.61M | $71.46M | $60.24M | $46.61M | $38.67M |
| SG&A expense | $492.55M | $418.56M | $385.64M | $322.20M | $274.84M |
| Operating income | -$57.41M | -$115.50M | -$125.16M | -$113.78M | -$99.94M |
| Interest expense | $13.15M | $12.82M | $3.65M | $4.14M | $1.17M |
| Pretax income | -$43.60M | -$112.72M | -$122.66M | -$115.89M | -$100.99M |
| Income tax | $953,000 | $565,000 | $750,000 | $269,000 | $367,000 |
| Net income | -$44.55M | -$113.29M | -$123.41M | -$116.16M | -$101.36M |
| EBITDA | -$36.71M | -$94.81M | -$108.86M | -$100.38M | -$90.14M |
| EPS (basic) | -1.39 | -3.63 | -4.04 | -3.88 | -3.46 |
| EPS (diluted) | -1.39 | -3.63 | -4.04 | -3.88 | -3.46 |
| Weighted avg. shares (diluted) | 32.00M | 31.20M | 30.53M | 29.92M | 29.33M |
| Balance sheet | |||||
| Cash & equivalents | $236.01M | $427.95M | $36.17M | $78.83M | $127.56M |
| Short-term investments | $347.75M | $115.96M | $97.59M | $134.31M | $111.57M |
| Receivables | $75.71M | $79.94M | $61.48M | $49.92M | $46.43M |
| Inventory | $21.63M | $14.04M | $13.97M | $15.15M | $10.27M |
| Current assets | $702.76M | $645.82M | $230.81M | $288.77M | $305.52M |
| PP&E, net | $151.60M | $125.09M | $104.11M | $75.67M | $55.94M |
| Goodwill | $862,000 | $862,000 | $862,000 | $862,000 | $862,000 |
| Total assets | $1.02B | $931.45M | $433.14M | $448.22M | $462.97M |
| Current liabilities | $151.89M | $110.92M | $107.37M | $89.10M | $87.85M |
| Short-term debt | — | — | — | $0 | $11.67M |
| Long-term debt | — | — | $34.95M | $34.94M | $9.69M |
| Total debt | — | — | $34.95M | $34.94M | $21.36M |
| Total liabilities | $867.30M | $840.54M | $223.05M | $208.41M | $183.45M |
| Shareholders' equity | $152.75M | $90.91M | $210.10M | $239.81M | $279.51M |
| Net debt | — | — | -$1.22M | -$43.90M | -$106.20M |
| Shares outstanding | 32.30M | 31.39M | 30.95M | 30.19M | 29.49M |
| Cash flow statement | |||||
| Operating cash flow | $80.86M | $3.39M | -$50.10M | -$23.01M | -$37.75M |
| Capital expenditure | $46.34M | $33.94M | $40.42M | $29.83M | $28.07M |
| Free cash flow | $34.52M | -$30.55M | -$90.53M | -$52.84M | -$65.82M |
| Investing cash flow | -$277.06M | -$122.98M | -$1.21M | -$52.43M | $105.26M |
| Financing cash flow | $12.61M | $511.38M | $8.82M | $26.72M | -$28.58M |
| Depreciation & amortization | $20.70M | $20.70M | $16.30M | $13.40M | $9.80M |
| Stock-based compensation | $88.28M | $75.98M | $77.20M | $57.74M | $54.53M |
| Share buybacks | $0 | $25.00M | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.